---
title: "One-Year Outcomes of the ISAR SUMMIT Polymer-Free Everolimus-Eluting Stent in Real-World PCI"
id: "medrxiv-15-one-year-safety-and-effectiveness-of-the-isar-summit-polymer-free-everolimus"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-15-one-year-safety-and-effectiveness-of-the-isar-summit-polymer-free-everolimus"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.07.16.26358282v1?rss=1"
published_at: "2026-07-18T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# One-Year Outcomes of the ISAR SUMMIT Polymer-Free Everolimus-Eluting Stent in Real-World PCI
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-15-one-year-safety-and-effectiveness-of-the-isar-summit-polymer-free-everolimus
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.07.16.26358282v1?rss=1)
- **Published At:** 2026-07-18T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The TRANSEVER registry prospectively evaluated 12-month clinical outcomes after percutaneous coronary intervention (PCI) using the **ISAR SUMMIT** **polymer-free everolimus-eluting stent** in a large, real-world Indian cohort across 33 centres. - A total of 1,000 patients were enrolled; 996 completed 12-month follow-up. The study population had a high-risk clinical profile: **acute coronary syndrome (ACS)** in 89.8% and diabetes mellitus in 44.4% of patients. - Procedural performance was strong: device success and final **TIMI 3 flow** were achieved in all treated lesions per the report. - The primary endpoint, **target-lesion failure (TLF)** at 12 months (composite of cardiac death, target-vessel myocardial infarction, or clinically driven target lesion revascularisation), occurred in 15 patients (1.5%). - Secondary outcomes included the patient-oriented composite endpoint (**POCE**) and stent thrombosis: POCE occurred in 21 patients (2.1%), and definite or probable **stent thrombosis** was reported in 8 patients (0.8%). - The authors conclude that, in this contemporary real-world population with a very high proportion presenting with ACS, the polymer-free everolimus-eluting ISAR SUMMIT stent showed favourable 12-month safety and effectiveness, with low rates of TLF and stent thrombosis. - The study is a clinical preprint (not yet peer reviewed), registered as CTRI/2022/07/044472, and was posted July 18, 2026. Ethics committee approvals at multiple Indian sites are documented. The authors reported no competing interests.
## Clinical Analysis & Structured Key Points
Skip to main content HOMESUBMITFAQBLOGALERTS / RSSRESOURCESABOUT Search for this keyword Advanced Search Follow this preprint One-Year Safety and Effectiveness of the ISAR SUMMIT Polymer-Free Everolimus-Eluting Stent in Real-World Clinical Practice Praveen Chandra, View ORCID Profile YASH Paul Sharma, Rajneesh Kapoor, Rahul Singhal, Pushpraj Patel, Anupam Jena, Dileep Kumar Tiwari, View ORCID Profile Rohit Mody, Amjad Ali, Aditya Kapoor, Preeti Sharma, Viveka Kumar, Kamal Sharma, Vikas Chopra, Milind Nivrutti Kharche, Vikas Kataria, Sameer Dani, DEEPAK DAVIDSON, Rajiv Agarwal, PLN Kapardy, Ripen Gupta, Rohan Ainchwar, Ashwani Mehta, Aziz Khan, Jaspal Arneja, View ORCID Profile Adnan Kastrati doi: https://doi.org/10.64898/2026.07.16.26358282 This article is a preprint and has not been certified by peer review [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice. AbstractInfo/HistoryMetrics Preview PDF Abstract Aims Polymer-free drug-eluting stents were developed to enhance vascular biocompatibility and safety while maintaining antirestenotic efficacy. The TRANSEVER registry evaluated 12-month clinical outcomes of the polymer-free everolimus-eluting ISAR SUMMIT stent in a large, real-world population undergoing percutaneous coronary intervention. Methods This prospective, multicentre study enrolled patients with coronary artery disease undergoing PCI with the ISAR SUMMIT stent across 33 centres in India. The primary endpoint was target-lesion failure (TLF) at 12 months, a composite of cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularisation. Secondary endpoints included the patient-oriented composite endpoint (POCE) of all-cause death, any myocardial infarction, stroke, revascularization, and definite/probable stent thrombosis. Results A total of 1,000 patients were enrolled, of whom 996 completed 12-month follow-up. The cohort presented with a high-risk profile, including an acute coronary syndrome (ACS) in 89.8% of the cases and diabetes mellitus in 44.4% of them. Procedural outcomes were excellent in terms of device success and final TIMI 3 flow (achieved in all treated lesions). At 12 months, TLF occurred in 15 patients (1.5%). Definite or probable stent thrombosis was observed in 8 patients (0.8%). POCE was observed in only 21 patients (2.1%). Conclusions In this large, contemporary real-world population with a very high proportion of patients presenting with ACS, the polymer-free everolimus-eluting ISAR SUMMIT stent demonstrated favourable 12-month clinical outcomes, with low rates of target lesion failure and stent thrombosis. These results suggest that this novel device is both safe and effective for routine clinical use. Competing Interest Statement The authors have declared no competing interest. Clinical Trial CTRI/2022/07/044472 Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: 1. Good Society for Ethical Research, D/129, St No-13, Ashok Nagar, Shahdara, Delhi - 110093 2. Ethics Committee Caritas Hospital, Caritas Hospital, Thellakom P O Kottayam Kerala - 686630 3. Ethics Committee of Crescent Hospital Heart Centre, Plot No 25, Behind Old Mount Carmel School, Near Lokmat Square, Dhantoli Nagpur, Maharashtra - 440012 4. Ethics Committee - Shalby Hospital Shalby Limited, Plot-B, Ahinsa Chowk, Kachnar City Road, Vijay Nagar, Jabalpur, Madhya Pradesh - 482002 India 5. Ethics Committee - Shalby Hospital Shalby Limited, Plot-B, Ahinsa Chowk, Kachnar City Road, Vijay Nagar, Jabalpur, Madhya Pradesh - 482002 India 6. Ethics Committee Kodlikeri Memorial Hospital & Group of CIIGMA Hospital, United CIIGMA Institute of Medical Sciences Pvt. Ltd., 3rd Floor, Plot No. 6, 7, Survey No. 10, Shahnoorwadi, Dargah Road Aurangabad, Maharashtra - 431005 India 7. Sanjivani Hospital Ethics Committee, Sanjivani Super Speciality Hospital Pvt. Ltd. 1, Uday Park Society, Near Sunrise Park, Vastrapur, Ahmedabad, Gujarat - 380015 India 8. Ethics Committee - Shalby Hospital Shalby Limited, Plot-B, Ahinsa Chowk, Kachnar City Road, Vijay Nagar, Jabalpur, Madhya Pradesh - 482002 India 9. Medanta Institutional Ethics Committee, Medanta-The Medicity, Sector 38, Gurugram, Haryana - 122001 India 10. Institutional Ethics Committee Anu Hospitals, Anu Hospitals, Kovelamudivari Street Suryaraopet Vijayawada Krishna Andhra Pradesh - 520002 India 11. Max Healthcare Ethics Committee, Ground Floor, Office of Ethics Committee, West block, Near MS Office, Max Super Speciality Hospital, Saket (A unit of Max Healthcare Institute Limited) 1, Press enclave Road, Saket, New Delhi, 110017 India 12. Arnejas Institutional Ethics Committee, 123, Ramdaspeth Behind Somalwar High School, Nagpur Maharashtra - 440010 India 13. Eternal Heart Care Centre and Res Inst-IEC, Eternal Heart Care Centre and Research Ins Pvt Ltd, 3 A Jagatpura Road, Near Jawahar Circle, Jaipur Rajasthan - 302017 India 14. Institutional Ethics Committee, Max Super Speciality Hospital, Bathinda Near District Civil Hospital, Mansa Road, Bathinda, Punjab 151001, India 15. Institutional Ethics Committee, Fortis Escorts Hospital, Jawahar Lal Nehru Marg, Malviya Nagar, Jaipur 302017, Rajasthan, India 16. Max Healthcare Ethics Committee, Max Healthcare Institute Limited, Max Super Speciality Hospital, 2, Press Enclave Road, Saket, New Delhi - 110017 17. Fortis Hospital Ethics Committee, Fortis Hospital Ltd, 154/9, Bannerghatta Road Opp to IIM-B Bangalore, Bengaluru (Bangalore) Urban Karnataka - 560076 India 18. Institutional Ethics Committee KIMS, Kalinga Institute of Medical Sciences, Kushabhadra campus (Campus 5) KIIT University, Patia Bhubaneswar Khordha Orissa - 751024 India 19. Institutional Ethics Committee Clinical Studies, Apollo Hospitals International Ltd, Plot No.1a, GIDC, Estate Bhat, Gandhinagar, Gujarat - 382428 India 20. Institutional Ethics Committee, Post Graduate Institute of Medical Education and Research, Room No. 6006, IEC Office, 6th Floor P N Chuttani Block, Chandigarh - 160012 India 21. Institutional Ethics Committee Anu Hospitals, Anu Hospitals, Kovelamudivari Street Suryaraopet Vijayawada Krishna Andhra Pradesh - 520002 India 22. Jasleen Hospital Ethics Committee, Jasleen Hospital Opp. big Bazar, Panchashil Square, Dhantoli Opp. big Bazar, Panchashil Square, Dhantoli, Nagpur, Maharashtra - 440012 23. Medanta Institutional Ethics Committee, Medanta- The Medicity Sector 38, Gurugram Haryana - 122001 India 24. Institutional Ethics Committee, Asian Institute of Gastroenterology, 3rd Floor, 6-3 661, Somajiguda, Hyderabad Telangana - 500082 India 25. CARE Hospitals, Institutional Ethics Committee, 6-3-248/2, Care Hospital, In-Patient building, 4th Floor Room No. 401, Road No-1, Banjara Hills Hyderabad Telangana 500034 India 26. Institutional Ethics Committee, Jehangir Clinical Development Center Pvt. Ltd, Jehangir hospital premises 32, Sasoon Road, Pune, Maharashtra - 411001 India 27. Institutional Ethics Committee, Max Super Speciality Hospital, Dehradun a unit of Max healthcare insititute limited, Max Super Speciality Hospital, Dehradun a unit of Max healthcare insititute limited, Near Indian Oil Petrol Pump, Malsi Estate, Mussoorie, DiversionRoad, Khasra No. 165, 166 Dehradun, Uttarakhand - 248001 28. Max Healthcare Ethics Committee, Max Healthcare Institute Limited, Max Super Speciality Hospital, 2, Press Enclave Road, Saket, New Delhi - 110017 29. CARE Hospitals, Institutional Ethics Committee, 6-3-248/2, Care Hospital, In-Patient building, 4th Floor Room No. 401, Road No-1, Banjara Hills Hyderabad Telangana 500034 India 30. Institutional Ethics Committee, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli Road, Lucknow, Uttar Pradesh - 226014 India 31. Sir Ganga Ram Hospital Ethics Committee, Sir Ganga Ram Hospital, Ethics Committee, Sir Ganga Ram Hospital Old, Rajinder Nagar, New Delhi 110060, India 32. Holy Family Hospital Ethical Committee Holy Family Hospital, Okhla Road, New Delhi, South Delhi - 110025 India 33. IEC-SAL Institute of Medical Sciences SIMS, SAL Institute of Medical Sciences-SIMS, Opposite Science City Sola Road Ahmedabad, Ahmedabad Gujarat - 380060 India I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license. bioRxiv and medRxiv thank the following for their generous financial support: The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. Donate to openRxiv Back to top Previous Next Posted July 18, 2026. Download PDF Print/Save Options Author Declarations Data/Code Email Share Citation Tools Get QR code Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos Subject Areas All Articles Addiction Medicine Allergy and Immunology Anesthesia Cardiovascular Medicine Dentistry and Oral Medicine Dermatology Emergency Medicine Endocrinology (including Diabetes Mellitus and Metabolic Disease) Epidemiology Forensic Medicine Gastroenterology Genetic and Genomic Medicine Geriatric Medicine Health Economics Health Informatics Health Policy Health Systems and Quality Improvement Hematology HIV/AIDS Infectious Diseases (except HIV/AIDS) Intensive Care and Critical Care Medicine Medical Education Medical Ethics Nephrology Neurology Nursing Nutrition Obstetrics and Gynecology Occupational and Environmental Health Oncology Ophthalmology Orthopedics Otolaryngology Pain Medicine Palliative Medicine Pathology Pediatrics Pharmacology and Therapeutics Primary Care Research Psychiatry and Clinical Psychology Public and Global Health Radiology and Imaging Rehabilitation Medicine and Physical Therapy Respiratory Medicine Rheumatology Sexual and Reproductive Health Sports Medicine Surgery Toxicology Transplantation Urology Evaluation/discussion of this paper x 0 0 0 0 0 0 We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. Continue Find out more
## Related Clinical Research

- [Stepwise DAPT de-escalation vs standard DAPT after drug-coated balloon angioplasty in multivessel](https://medichelpline.com/clinical-feed/medrxiv-15-impact-of-stepwise-dual-antiplatelet-therapy-de-escalation-in-patients-with.md)
- [Ticagrelor versus Prasugrel After PCI for Acute Coronary Syndrome: Multinational Comparative Effec](https://medichelpline.com/clinical-feed/medrxiv-23-comparative-effectiveness-of-ticagrelor-vs-prasugrel-in-patients-with-acute.md)
- [Semaglutide and Primary Prevention of MACCE in Obese Adults with T2DM and Rheumatoid Arthritis](https://medichelpline.com/clinical-feed/pubmed-42334436.md) (DOI: 10.1093/ehjcvp/pvag044)
- [Optimal DAPT Duration After PCI with Contemporary DES: Network Meta-analysis of RCTs](https://medichelpline.com/clinical-feed/plos-one-7-dual-antiplatelet-therapy-duration-after-percutaneous-coronary-intervention.md)
- [Genistein modifies the association between EASIX and estimated 10-year ASCVD risk](https://medichelpline.com/clinical-feed/plos-one-13-interaction-between-genistein-and-the-endothelial-activation-and-stress-index.md)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.